Get the Stockscreener App
19.23
1.21%
0.23
After Hours:
19.23
Avalo Therapeutics Inc stock is traded at $19.23, with a volume of 633.22K.
It is up +1.21% in the last 24 hours and up +3.78% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
See More
Previous Close:
$19.00
Open:
$18.81
24h Volume:
633.22K
Relative Volume:
0.50
Market Cap:
$1.03B
Revenue:
$59,000
Net Income/Loss:
$-84.74M
P/E Ratio:
-3.3029
EPS:
-5.8222
Net Cash Flow:
$-59.69M
1W Performance:
-1.84%
1M Performance:
+3.78%
6M Performance:
+4.74%
1Y Performance:
+89.27%
1-Day Range:
$18.79
$19.62
1-Week Range:
$18.73
$19.86
52-Week Range:
$9.54
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
19.23 | 1.06B | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Apr-06-26 | Initiated | Citizens | Mkt Outperform |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
(AVTX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
Avalo Therapeutics Inc. (AVTX) Peer Comparison – Compare with Others - Value Research
Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX) - Seeking Alpha
Avalo Therapeutics Inc. (AVTX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock By Investing.com - Investing.com South Africa
Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock - Investing.com
Avalo Therapeutics CFO Sullivan sells over $1.4m in stock By Investing.com - Investing.com Canada
Avalo Therapeutics (AVTX) CMO trades shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc. (AVTX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
How Avalo Therapeutics Inc. (AVTX) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Avalo Therapeutics CFO sells over $1.45 million in stock By Investing.com - Investing.com Nigeria
Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares - Investing.com
AVTX | Avalo Therapeutics, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Avalo Therapeutics, Inc. Revenue Breakdown – NASDAQ:AVTX - TradingView
Deep Track Capital, LP Expands Avalo Therapeutics Inc (AVTX) Sta - GuruFocus
Avalo (AVTX) Q2 2026 Earnings: The EPS Result Is Below Expectation in the Latest Session; Post-Report: Shares Move 5.28% UpRevenue Growth Outlook - vinanet.vn
Avalo Therapeutics CMO Mittie Doyle Executes Stock Option and Sells 1,000 Shares Under 10b5-1 Plan - Kalkine Media
Avalo Therapeutics (AVTX) CMO sells 1,000 shares in plan - Stock Titan
Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing - marketscreener.com
Avalo Therapeutics (AVTX) CFO sells 72K shares in 10b5-1 trades - Stock Titan
Avalo (AVTX) Financial Update: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Report - vinanet.vn
Avalo Therapeutics (NASDAQ: AVTX) insider lines up new stock sale after $74K August trade - Stock Titan
Avalo Therapeutics (AVTX) insider lines up $98.7K stock sale - Stock Titan
Avalo Therapeutics, Inc. SEC Filing (Aug 17, 2026) - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) insider to sell shares - Stock Titan
AVTX Q2 2026 Earnings: Wider-than-Expected Loss of -$0.83 Per Share Highlights Clinical-Stage BurnRevenue Growth Report - Vinanet
Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold - marketbeat.com
Why Did AVTX Stock Surge 45% In Pre-Market Today? - Stocktwits
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock By Investing.com - Investing.com Australia
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock By Investing.com - Investing.com Canada
Avalo Therapeutics CSO Jennifer Riley sells $52,012 in stock - Investing.com
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock - Investing.com
AVTX Surges Over 50% After Hours as Skin Disease Drug Shows Desired Clinical Results - Stocktwits
Avalo Therapeutics Stock Price Forecast. Should You Buy AVTX? - StockInvest.us
Avalo Therapeutics (AVTX): Nantahala Capital discloses 3.54% ownership stake - Stock Titan
Caligan Partners (NASDAQ: AVTX) reports 5.9% Avalo Therapeutics ownership on amended 13G - Stock Titan
RA Capital discloses 3.48M-share Avalo Therapeutics (AVTX) position in latest filing - Stock Titan
Avalo Therapeutics (AVTX): BVF group discloses 5.3% beneficial ownership stake - Stock Titan
Avalo Therapeutics (AVTX) sees T. Rowe Price report 3,670-share holding - Stock Titan
Avalo Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | C6K0 | US05338F3064 - marketscreener.com
Avoro Capital and Behzad Aghazadeh report 4.44% AVTX stake in 13G/A filing - Stock Titan
Deep Track Capital (AVTX) discloses 3.61M-share, 6.87% stake in Avalo - Stock Titan
Sei Investments Co. Invests $849,000 in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Avalo Therapeutics (AVTX) sees 5.5% stake reported by Affinity Asset Advisors and Michael Cho - Stock Titan
Avalo Therapeutics (AVTX) Chief Strategy Officer Jennifer Riley Sells 2,655 Shares - GuruFocus
Avalo Therapeutics (AVTX) CMO Mittie Doyle exercises options and sells 679 shares - Stock Titan
Avalo Therapeutics (AVTX) CSO Riley sells 2,655 shares at about $19.59 - Stock Titan
Avalo Therapeutics, Inc. $AVTX Shares Bought by Renaissance Technologies LLC - MarketBeat
Avalo Therapeutics (AVTX) insider plans NASDAQ resale of 2,655 ESPP shares - Stock Titan
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Option Exercise |
9.88 |
31,031 |
306,586 |
70,931 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 17 '26 |
Sale |
19.86 |
41,694 |
828,096 |
39,900 |
| Sullivan Christopher Ryan | Chief Financial Officer |
Aug 18 '26 |
Sale |
20.05 |
31,031 |
622,324 |
39,900 |
| Doyle Mittie | Chief Medical Officer |
Aug 17 '26 |
Option Exercise |
12.65 |
1,000 |
12,650 |
52,776 |
| Doyle Mittie | Chief Medical Officer |
Aug 17 '26 |
Sale |
20.00 |
1,000 |
20,000 |
51,776 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):